Galena Biopharma (GALE) CEO Dr. Mark Ahn is Well-Versed in Biopharm, Corporate Management

MissionIR would like to highlight Galena Biopharma (NASDAQ: GALE), focused on developing and commercializing targeted oncology treatments to address major unmet medical needs and advance cancer care. The company’s peptide vaccine immunotherapies harness the patient’s own immune system to identify and destroy cancer cells. Utilizing peptide immunogens has many clinical advantages, including an excellent safety profile and long-lasting protection through immune system activation and convenient delivery.

In the company’s news,

Galena Biopharma is a biopharmaceutical company focused on developing and commercializing treatments to address major unmet medical needs in the field of oncology. As GALE works to expand its drug candidate portfolio, the company’s stated mission is to accelerate value for both patients and company shareholders, a goal that requires support and guidance from an experienced and aggressive management team.

Leading the company’s corporate initiatives is Mark J. Ahn, Ph.D., who has more than 20 years of experience in the biopharmaceutical industry. Dr. Ahn has served as GALE’s president and CEO since March 2011, and has also served as a director of the company since 2007.

Prior to joining GALE, Dr. Ahn was principal at Pukana Partners, Ltd., which provides strategic consulting to life science companies; and associate professor of Global Management at Atkinson Graduate School of Management, Willamette University. He also previously served as professor and chair of Science & Technology Management for Victoria University at Wellington, New Zealand.

Dr. Ahn was also founder and was previously the president and CEO of Hana Biosciences following his employment as vice president of Hematology and corporate officer at Genentech, Inc. In addition, he has held positions of increasing responsibility at Amgen (AMGN) and Bristol-Myers Squibb (BMY).

Dr. Ahn has authored more than 50 peer reviewed journal articles and books, and serves on public and venture capital-backed board of directors for Access Pharmaceuticals, Mesynthes, and ScribesSTAT. He received a BA and an MBA from Chaminade University, as well as an MA from Victoria University. Furthermore, Dr. Ahn was a graduate fellow in economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr. Ahn is a Henry Crown Fellow at the Aspen Institute.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.